Site Map

About ONYDA XR

PK Data

Efficacy

Safety Data

Dosing

Patient Profiles

Advanced Technology

Request More Info

Savings & Support

HCP Resources

About ADHD

Back to Top arrow up
IMPORTANT SAFETY INFORMATION

ONYDA™ XR (clonidine HCI) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

See Additional Important Safety Information.

INDICATION

ONYDA™ XR (clonidine HCI) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications:

ONYDA XR is contraindicated in patients with history of a hypersensitivity reaction to clonidine.

Warnings & Precautions:

Adverse Reactions:

Clinically Important Drug Interactions:

Use in Specific Populations:

To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at 1-732-940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see ONYDA XR PI for Full Prescribing Information.

You are now leaving this website

You are about to leave ONYDAhcp.com and enter a website operated by a third party. Would you like to continue?

Yes
×
Interested in more information?

To learn more about Tris ADHD products, or to speak to a representative, please click below.

Request Info
up arrowTop